MARKET

COAG

COAG

HEMAB THERAPEUTICS HOLDINGS
NASDAQ
38.40
+2.38
+6.61%
After Hours: 38.40 0 0.00% 16:17 10/27 EDT
OPEN
36.35
PREV CLOSE
36.02
HIGH
38.58
LOW
35.41
VOLUME
380.01K
TURNOVER
--
52 WEEK HIGH
55.42
52 WEEK LOW
23.00
MARKET CAP
1.79B
P/E (TTM)
-37.2635
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at COAG last week (1019-1023)?
Weekly Report · 1d ago
Weekly Report: what happened at COAG last week (1012-1016)?
Weekly Report · 10/19 10:32
Analysts Offer Insights on NA Companies: Cleanspark (CLSK), Hemab Therapeutics Holdings, Inc. (COAG) and Microsoft (MSFT)
TipRanks · 10/16 10:30
Hemab Therapeutics Initiated at Overweight by JP Morgan
Dow Jones · 10/15 22:40
Hemab Therapeutics Price Target Announced at $70.00/Share by JP Morgan
Dow Jones · 10/15 22:40
JP Morgan Initiates Coverage On Hemab Therapeutics Hldgs with Overweight Rating, Announces Price Target of $70
Benzinga · 10/15 13:14
Hemab Therapeutics initiated with an Overweight at JPMorgan
TipRanks · 10/15 09:40
Rodman & Renshaw Initiates Coverage of Hemab Therapeutics Holdings with Buy
NASDAQ · 10/12 22:24
More
About COAG
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company. The Company is developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. It designs its assets to address critical gaps in the treatment of coagulation disorders. Its lead asset, sutacimig (HMB-001), is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Its second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. HMB-002 is designed to address the underlying biological drivers of Von Willebrand Disease by increasing endogenous levels of von Willebrand factor (VWF), and Factor VIII, a blood coagulation protein. It is also advancing multiple preclinical and discovery-stage assets.

Webull offers Hemab Therapeutics Holdings, Inc. stock information, including NASDAQ: COAG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COAG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COAG stock methods without spending real money on the virtual paper trading platform.